Subgroup analyses of outcomes following development of disease refractory to a CD38-targeting agent suggested that carfilzomib + an alkylator have some efficacy.
Twice-weekly administration of carfilzomib requires patients to receive carfilzomib infusions on 2 consecutive days each week.
The efficacy and safety of autologous hematopoietic stem cell transplantation (auto-HCT) performed during the era of novel agents was comparable between elderly and younger patients with multiple myeloma, according to results of a retrospective study published in Bone Marrow Transplantation. Uncertainty remains regarding the risks and benefits of auto-HCT in elderly patients (≥ 65 years).…
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Takeda will work with Memorial Sloan Kettering Cancer Center to develop CAR-T therapies for multiple myeloma.
Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.
Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).
CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.
A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.
BCMA expression did not correlate with clinical response.
Patients saw a deepening of responses over time.
Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.
AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.
Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Stringent CR criteria may not predict clinical outcomes for patients with MM.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.